What happened
IL Dong Pharmaceutical filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$95.3M (+4.4% year on year), operating profit of US$6.19M (+120% year on year) and net income of US$4.95M (+1376.6% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$95.3M |
|---|---|
| Revenue vs a year earlier | +4.4% |
| Operating profit | US$6.19M |
| Net income | US$4.95M |
| Period | Q1 2026 (consolidated) |
| Filed | 2026-05-13, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260513800538 → open original filing |
Source: DART. Information only, not investment advice.